| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Björn Falkenburger, Theodoros Kalliakoudas, Heinz Reichman. Adaptive changes in striatal projection neurons explain the long duration response and the emergence of dyskinesias in patients with Parkinson's disease. Journal of neural transmission (Vienna, Austria : 1996). 2022-05-10. PMID:35538324. |
moreover, dyskinesias are considered signs of excessive dopaminergic neurotransmission in parkinson's disease, but they are typically more severe on the body side that is more strongly affected by dopamine depletion. |
2022-05-10 |
2023-08-13 |
Not clear |
| M Angela Cenci, Katrine Skovgård, Per Odi. Non-dopaminergic approaches to the treatment of motor complications in Parkinson's disease. Neuropharmacology. 2022-03-16. PMID:35292330. |
dopamine replacement therapy with l-dopa is the most efficacious symptomatic treatment for parkinson's disease, but its utility is limited by the development of motor fluctuations and abnormal involuntary movements (dyskinesia) in a majority of the patients. |
2022-03-16 |
2023-08-13 |
Not clear |
| Samantha Smith, Jordan Sergio, Michael Coyle, Kayla Elder, Ashley Centner, Sophie Cohen, Michelle Terry, Natalie Lipari, John Glinski, Emily Wheelis, Carla Budrow, Christopher Bisho. The effects of Vilazodone, YL-0919 and Vortioxetine in hemiparkinsonian rats. Psychopharmacology. 2022-03-11. PMID:35275226. |
growing evidence shows that with burgeoning dopamine cell loss, neuroplasticity in the serotonin system leads to the development of l-dopa-induced dyskinesia through the unregulated uptake, conversion, and release of l-dopa-derived dopamine into the striatum. |
2022-03-11 |
2023-08-13 |
rat |
| Cheol-Hyun Kim, Jeeyoun Jung, Young-Ung Lee, Kwang-Ho Kim, Sunny Kang, Geon-Hui Kang, Hongmin Chu, Se-Young Kim, Sangkwan Le. Comparison of Metabolites and Gut Microbes between Patients with Parkinson's Disease and Healthy Individuals-A Pilot Clinical Observational Study (STROBE Compliant). Healthcare (Basel, Switzerland). vol 10. issue 2. 2022-02-25. PMID:35206916. |
even if levodopa, dopamine agonists, and others are used for patients with parkinson's disease, the effect is not sustained, and side effects such as motor fluctuation and dyskinesia are more likely to appear as the dose increases. |
2022-02-25 |
2023-08-13 |
Not clear |
| Xiao-Zhong Jing, Xiang-Zhen Yuan, Xingguang Luo, Shu-Yun Zhang, Xiao-Ping Wan. An Update on Nondopaminergic Treatments for Motor and Non-motor symptoms of Parkinson's disease. Current neuropharmacology. 2022-02-23. PMID:35193486. |
the most promising research area of nondopaminergic targets is to reduce motor complications caused by traditional dopamine replacement therapy, including motor fluctuations and levodopa induced dyskinesia. |
2022-02-23 |
2023-08-13 |
human |
| Haruo Nishijima, Fumiaki Mori, Tamaki Kimura, Yasuo Miki, Iku Kinoshita, Takashi Nakamura, Tomoya Kon, Chieko Suzuki, Koichi Wakabayashi, Masahiko Tomiyam. Cabergoline, a long-acting dopamine agonist, attenuates L-dopa-induced dyskinesia without L-dopa sparing in a rat model of Parkinson's disease. Neuroscience research. 2022-02-12. PMID:35150767. |
cabergoline, a long-acting dopamine agonist, attenuates l-dopa-induced dyskinesia without l-dopa sparing in a rat model of parkinson's disease. |
2022-02-12 |
2023-08-13 |
rat |
| Carissa A Hansen, Douglas R Miller, Stephanie Annarumma, Carley T Rusch, Adolfo Ramirez-Zamora, Habibeh Khoshboue. Levodopa-induced dyskinesia: a historical review of Parkinson's disease, dopamine, and modern advancements in research and treatment. Journal of neurology. 2022-01-18. PMID:35039902. |
levodopa-induced dyskinesia: a historical review of parkinson's disease, dopamine, and modern advancements in research and treatment. |
2022-01-18 |
2023-08-13 |
Not clear |
| Jared T Hinkle, Kate Perepezko, Lorenzo L Gonzalez, Kelly A Mills, Gregory M Ponton. Apathy and Anxiety in De Novo Parkinson's Disease Predict the Severity of Motor Complications. Movement disorders clinical practice. vol 8. issue 1. 2021-12-05. PMID:33426161. |
some evidence suggests that they may also signify risk for motor complications (motor fluctuations and dyskinesias) of dopamine replacement therapy (drt). |
2021-12-05 |
2023-08-13 |
Not clear |
| Thomas Oh, Elyas S Daadi, Jeffrey Kim, Etienne W Daadi, Peng-Jen Chen, Gourav Roy-Choudhury, Jonathan Bohmann, Benjamin E Blass, Marcel M Daad. Dopamine D3 receptor ligand suppresses the expression of levodopa-induced dyskinesia in nonhuman primate model of parkinson's disease. Experimental neurology. vol 347. 2021-12-03. PMID:34762921. |
dopamine d3 receptor ligand suppresses the expression of levodopa-induced dyskinesia in nonhuman primate model of parkinson's disease. |
2021-12-03 |
2023-08-13 |
Not clear |
| Daniel Weiss, Jens Volkmann, Alfonso Fasano, Andrea Kühn, Paul Krack, Günther Deusch. Changing Gears - DBS For Dopaminergic Desensitization in Parkinson's Disease? Annals of neurology. vol 90. issue 5. 2021-12-01. PMID:34235776. |
we review the clinical presentations of 'dopaminergic sensitization', including rebound off and dyskinesia in the motor domain, and neuropsychiatric fluctuations and behavioral addictions with impulse control disorders and dopamine dysregulation syndrome in the neuropsychiatric domain. |
2021-12-01 |
2023-08-13 |
Not clear |
| Rajeev K Singla, Tanya Agarwal, Xuefei He, Bairong She. Herbal Resources to Combat a Progressive & Degenerative Nervous System Disorder- Parkinson's Disease. Current drug targets. vol 22. issue 6. 2021-11-26. PMID:33050857. |
parkinson's disease is one of the most common adult-onset, a chronic disorder involving neurodegeneration, which progressively leads to deprivation of dopaminergic neurons in substantia nigra, causing a subsequent reduction of dopamine levels in the striatum resulting in tremor, myotonia, and dyskinesia. |
2021-11-26 |
2023-08-13 |
Not clear |
| Keita Sugiyama, Mahomi Kuroiwa, Takahide Shuto, Yoshinori N Ohnishi, Yukie Kawahara, Yuta Miyamoto, Takaichi Fukuda, Akinori Nish. Subregion-Specific Regulation of Dopamine D1 Receptor Signaling in the Striatum: Implication for L-DOPA-Induced Dyskinesia. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 41. issue 30. 2021-11-22. PMID:34131032. |
subregion-specific regulation of dopamine d1 receptor signaling in the striatum: implication for l-dopa-induced dyskinesia. |
2021-11-22 |
2023-08-13 |
mouse |
| Vishakh Iyer, Kala Venkiteswaran, Sandip Savaliya, Christopher A Lieu, Erin Handly, Timothy P Gilmour, Allen R Kunselman, Thyagarajan Subramania. The cross-hemispheric nigrostriatal pathway prevents the expression of levodopa-induced dyskinesias. Neurobiology of disease. vol 159. 2021-11-18. PMID:34461264. |
unfortunately, long-term dopamine replacement therapy using levodopa leads to levodopa-induced dyskinesias (lid), a significant and disabling side-effect. |
2021-11-18 |
2023-08-13 |
rat |
| Feras Altwal, Fernando E Padovan-Neto, Alexandra Ritger, Heinz Steiner, Anthony R Wes. Role of 5-HT1A Receptor in Vilazodone-Mediated Suppression of L-DOPA-Induced Dyskinesia and Increased Responsiveness to Cortical Input in Striatal Medium Spiny Neurons in an Animal Model of Parkinson's Disease. Molecules (Basel, Switzerland). vol 26. issue 19. 2021-11-16. PMID:34641332. |
research has identified abnormal dopamine release from serotonergic (5-ht) terminals contributing to this dyskinesia. |
2021-11-16 |
2023-08-13 |
Not clear |
| Vibhash D Sharma, Harsh V Gupta, Alberto J Espa. Copulatory Dyskinesia: Pathognomonic Manifestation of Tardive Dyskinesia. Tremor and other hyperkinetic movements (New York, N.Y.). vol 10. 2021-11-15. PMID:33362950. |
copulatory or pelvic thrusting dyskinesia is a subtype of tardive dyskinesia (td) which is caused by exposure to dopamine blocking agents. |
2021-11-15 |
2023-08-13 |
Not clear |
| Emma L Lane, David J Harrison, Elena Ramos-Varas, Rachel Hills, Sophie Turner, Mariah J Lelo. Spontaneous Graft-Induced Dyskinesias Are Independent of 5-HT Neurons and Levodopa Priming in a Model of Parkinson's Disease. Movement disorders : official journal of the Movement Disorder Society. 2021-11-12. PMID:34766658. |
current theories implicate the presence of grafted serotonin neurons, hotspots of dopamine release, neuroinflammation and established levodopa-induced dyskinesia. |
2021-11-12 |
2023-08-13 |
Not clear |
| Koki Nagaoka, Takuya Nagashima, Nozomi Asaoka, Hiroki Yamamoto, Chihiro Toda, Gen Kayanuma, Soni Siswanto, Yasuhiro Funahashi, Keisuke Kuroda, Kozo Kaibuchi, Yasuo Mori, Kazuki Nagayasu, Hisashi Shirakawa, Shuji Kanek. Striatal TRPV1 activation by acetaminophen ameliorates dopamine D2 receptor antagonist-induced orofacial dyskinesia. JCI insight. vol 6. issue 10. 2021-11-04. PMID:33857021. |
striatal trpv1 activation by acetaminophen ameliorates dopamine d2 receptor antagonist-induced orofacial dyskinesia. |
2021-11-04 |
2023-08-13 |
mouse |
| Koki Nagaoka, Takuya Nagashima, Nozomi Asaoka, Hiroki Yamamoto, Chihiro Toda, Gen Kayanuma, Soni Siswanto, Yasuhiro Funahashi, Keisuke Kuroda, Kozo Kaibuchi, Yasuo Mori, Kazuki Nagayasu, Hisashi Shirakawa, Shuji Kanek. Striatal TRPV1 activation by acetaminophen ameliorates dopamine D2 receptor antagonist-induced orofacial dyskinesia. JCI insight. vol 6. issue 10. 2021-11-04. PMID:33857021. |
analysis of the us food and drug administration adverse event reporting system and jmdc insurance claims revealed that acetaminophen prevented the dyskinesia induced by dopamine d2 receptor antagonists. |
2021-11-04 |
2023-08-13 |
mouse |
| Margaret E Caulfield, Jennifer A Stancati, Kathy Steece-Collie. Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease. Journal of visualized experiments : JoVE. issue 176. 2021-11-01. PMID:34723950. |
however, unwanted involuntary movements known as l-dopa-induced dyskinesias (lids) develop with prolonged use of this dopamine precursor. it is estimated that the incidence of lids escalates to approximately 90% of individuals with pd within 10-15 years of treatment. |
2021-11-01 |
2023-08-13 |
rat |
| Sara Corsi, Roberto Stancampiano, Manolo Cart. Serotonin/dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesia: An update. Progress in brain research. vol 261. 2021-10-22. PMID:33785132. |
in this review, we focus on the interplay between dopamine and serotonin in the appearance of l-dopa-induced dyskinesia (lid), the most troublesome side effect of l-dopa therapy. |
2021-10-22 |
2023-08-13 |
Not clear |